Oxford Biodynamics Plc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oxford Biodynamics Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014235
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oxford Biodynamics Plc (Oxford Biodynamics) is a biotechnology company that discovers and develops biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neurodegenerative conditions. Its biomarker discovery platform is used for the detection of aberrant gene expression. The company’s products are used in the areas of breast cancer diagnostics, hepatocellular carcinoma diagnostics, nasopharyngeal carcinoma diagnostics, prostate cancer progression, melanoma diagnostics, and age related disease diagnostics. Oxford Bio is headquartered in Oxford, the UK.

Oxford Biodynamics Plc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oxford Biodynamics Plc, Medical Devices Deals, 2011 to YTD 2017 9
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Oxford Biodynamics Raises US$3.2 Million In Financing 11
Partnerships 12
Oxford BioDynamics Enters into Agreement with US Biopharma Company 12
Oxford Biodynamics Enters into Development Agreement with Two Pharmaceutical Companies 13
Equity Offering 14
Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares 14
Oxford Biodynamics Plc – Key Competitors 15
Oxford Biodynamics Plc – Key Employees 16
Oxford Biodynamics Plc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Jun 13, 2017: Oxford Biodynamics Interim Results For The Six-Month Period Ended 31 March 2017 18
Jan 31, 2017: Oxford BioDynamics Announces Final Results for the Year Ended 30 September 2016 24
Corporate Communications 26
Sep 15, 2017: Oxford BioDynamics appoints Paul Stockdale as Chief Financial Officer and Executive Director on the Board 26
Jun 30, 2017: Oxford BioDynamics: Appointment of Paul Stockdale as Chief Financial Officer 27
Mar 09, 2017: Oxford BioDynamics announces appointment of Martin Reeves as Senior Vice President of Commercial Development 28
Feb 13, 2017: Oxford BioDynamics appoints Dr Claudio Carini as an Advisor 29
Government and Public Interest 30
Mar 17, 2017: Oxford BioDynamics announces collaboration to identify biological factors that trigger disease relapses in Rheumatoid Arthritis 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Key Facts 2
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oxford Biodynamics Plc, Deals By Therapy Area, 2011 to YTD 2017 8
Oxford Biodynamics Plc, Medical Devices Deals, 2011 to YTD 2017 9
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oxford Biodynamics Raises US$3.2 Million In Financing 11
Oxford BioDynamics Enters into Agreement with US Biopharma Company 12
Oxford Biodynamics Enters into Development Agreement with Two Pharmaceutical Companies 13
Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares 14
Oxford Biodynamics Plc, Key Competitors 15
Oxford Biodynamics Plc, Key Employees 16
Oxford Biodynamics Plc, Other Locations 17

★海外企業調査レポート[Oxford Biodynamics Plc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wolters Kluwer nv:企業の戦略・SWOT・財務情報
    Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report Summary Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ABB Ltd (ABBN):企業の財務・戦略的SWOT分析
    ABB Ltd (ABBN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • British Arab Commercial Bank plc:企業の戦略的SWOT分析
    British Arab Commercial Bank plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Saskatchewan Power Corp:企業の戦略的SWOT分析
    Saskatchewan Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Yandex NV (YNDX):企業の財務・戦略的SWOT分析
    Yandex NV (YNDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • DH Private Equity Partners:企業の戦略・SWOT・財務情報
    DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report Summary DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Nipro Corp (8086):医療機器:M&Aディール及び事業提携情報
    Summary Nipro Corp (Nipro) manufactures, develops and markets pharmaceuticals, medical equipment and functional materials (including glass, rubber and plastic). The company’s products include renal products, interventional and anesthesiology products, injection and infusion products, cardiopulmonary …
  • Difference Capital Financial Inc.:企業のM&A・事業提携・投資動向
    Difference Capital Financial Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Difference Capital Financial Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Genentech, Inc.:企業の戦略・SWOT・財務情報
    Genentech, Inc. - Strategy, SWOT and Corporate Finance Report Summary Genentech, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Copart Inc (CPRT):企業の財務・戦略的SWOT分析
    Summary Copart Inc (Copart) carries out the provision of auctions and vehicle marketing services. The company offers sales and marketing of early and late model, hybrid, featured and seller certified vehicles. It markets vehicles which include ATVs, exotic and classic cars, boats, dirt bikes, trucks …
  • BMO Private Bank:企業の戦略・SWOT・財務情報
    BMO Private Bank - Strategy, SWOT and Corporate Finance Report Summary BMO Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Arc Logistics Partners LP (ARCX):石油・ガス:M&Aディール及び事業提携情報
    Summary Arc Logistics Partners LP (Arc Logistics Partners) is an oil and gas company that provides energy logistics services. The company owns and operates terminaling, storage, rail, transloading, and pipeline assets. It transports various products including gasoline, distillates, fuels, aviation g …
  • CytomX Therapeutics Inc (CTMX):企業の財務・戦略的SWOT分析
    Summary CytomX Therapeutics Inc (CytomX) is a clinical-stage biopharmaceutical company which develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, probody drug conjuga …
  • ET Solar Group Corporation-エネルギー分野:企業M&A・提携分析
    Summary ET Solar Group Corporation (ET Solar) is a provider of renewable energy equipment and services. The company produces a wide variety of photovoltaic (PV) modules based on global standards such as IEC, TUV, VDE, and UL. It also provides horizontally integrated project development; finance and …
  • CardioDx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CardioDx Inc (CardioDx) is a cardiovascular genomic diagnostics company. It undertakes the development of clinically validated tests in the areas of coronary artery disease, cardiac arrhythmias and heart failure. The company’s flagship product, Corus CAD gene expression test is used for asse …
  • Intrexon Corp (XON)-製薬・医療分野:企業M&A・提携分析
    Summary Intrexon Corp (Intrexon), formerly Genomatix Corp is a provider of therapeutic solutions. The company operates through its divisions such as human therapeutics, protein production, industrial products, agricultural biotech, and animal sciences. Its human therapeutics division develops therap …
  • Immune Pharmaceuticals Inc (IMNP):製薬・医療:M&Aディール及び事業提携情報
    Summary Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designe …
  • ITT Inc (ITT):企業の財務・戦略的SWOT分析
    ITT Inc (ITT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • International Speedway Corporation:企業の戦略・SWOT・財務分析
    International Speedway Corporation - Strategy, SWOT and Corporate Finance Report Summary International Speedway Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Enerjisa Enerji Uretim AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from natural gas, lignite coal, hydro, and wind sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆